Hybridisation of [ 76Br]-labelled antisense oligonucleotides to Chromogranin A mRNA verified by RT-PCR

Nuclear Medicine and Biology

Volumn 31, Issue 8, 2004, Pages 1073-1078

  Wu, Feng ^a   Lendvai, Gabor ^a   Yngve, Ulrika ^a,b   Eriksson, Barbro ^c   Långström, Bengt ^a,b   Bergström, Mats ^a,b,d  

^a PO Box 967 751 85 Uppsala   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d Uppsala Imanet AB   (Sweden)

Author keywords

Antisense oligonucleotides; Autoradiography; Chromogranin A; Position emission tomography (PET); RT PCR

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BROMINE; CHROMOGRANIN A; MESSENGER RNA; RADIOISOTOPE; CHROMOGRANIN; CHROMOGRANIN A, RAT; OLIGONUCLEOTIDE; RADIOPHARMACEUTICAL AGENT;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DATA BASE; GEL ELECTROPHORESIS; GENE SEQUENCE; HEART; HYBRIDIZATION; ISOTOPE LABELING; KIDNEY; LIVER; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANTIBODY SPECIFICITY; EVALUATION; GENE SILENCING; GENETICS; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; BROMINE RADIOISOTOPES; CHROMOGRANIN A; CHROMOGRANINS; GENE SILENCING; ISOTOPE LABELING; MALE; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 10644282330     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.06.006     Document Type: Article

References (26)

1. K.M. Standifer, S. Jenab, W. Su, C.C. Chien, Y.X. Pan, and C.E. Inturrisi Antisense deoxynucleotides to the cloned δ receptor, DOR-1: uptake, stability, and regulation of gene expression J. Neurochem. 65 1995 1981 1987
2. R. Hanecak, V. Brown-Driver, M.C. Fox, R.F. Azad, S. Furusako, and C. Nozaki Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes J. Virol. 70 1996 5203 5212
3. J. Lai, T.J. Crook, A. Payne, R.M. Lynch, and F. Porreca Antisense targeting of delta opioid receptors in NG 108-15 cells: direct correlation between oligodeoxynucleotide uptake and receptor density J. Pharmacol. Exp. Ther. 281 1997 589 596
4. J. Lai, M. Riedl, L.S. Stone, U. Arvidsson, E.J. Bilsky, and G.L. Wilcox Immunofluorescence analysis of antisense oligodeoxynucleotide-mediated "knock-down" of the mouse delta opioid receptor in vitro and in vivo Neurosci. Lett. 213 1996 205 208
5. E.J. Bilsky, R.N. Bernstein, V.J. Hruby, R.B. Rothman, J. Lai, and F. Porreca Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo J. Pharmacol. Exp. Ther. 277 1996 491 501
6. S.A. Edsall, R.J. Knapp, T.W. Vanderah, W.R. Roeske, P. Consroe, and H.I. Yamamura Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception NeuroReport 7 1996 593 596
7. R.G. Amado, R.T. Mitsuyasu, and J.A. Zack Gene therapy for the treatment of AIDS: animal models and human clinical experience Front. Biosci. 4 1999 D468 D475
8. J. Herman, H. Adler, E. Aguilar-Cordova, A. Rojas-Martinez, S. Woo, and T. Timme In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial Hum. Gene Ther. 10 1999 1239 1249
9. J.B. Opalinska, and A.M. Gewirtz Nucleic-acid therapeutics: basic principles and recent applications Nat. Rev. Drug Discov. 1 2002 503 514
10. 76Br by a low energy cyclotron Appl. Radiat. Isot. 49 1998 1537 1540
11. K. Oberg Biochemical diagnosis of neuroendocrine GEP tumor Yale J. Biol. Med. 70 1997 501 508
12. L. Ferrari, E. Seregni, A. Martinetti, B. Van Graafeiland, S. Nerini-Molteni, and C. Botti Chromogranin A measurement in neuroendocrine tumors Int. J. Biol. Markers 13 1998 3 9
13. B. Eriksson, K. Oberg, and M. Stridsberg Tumor markers in neuroendocrine tumors Digestion 62 Suppl. 1 2000 33 38
14. 76Br]bromobenzoate and its use in conjugation labelling of macromolecules Acta Chem. Scand. 53 1999 508 512
15. 76Br-labeled antisense oligonucleotides of different length determined ex vivo in rats Eur. J. Pharm. Sci. 10 2000 179 186
16. 79Br using packed capillary liquid chromatography mass spectrometry Nucl. Med. Biol. 27 2000 851 853
17. 11C)Ro 15-1788 Nucl. Med. Biol. 24 1997 723 731
18. P.J. Leedman, A.R. Stein, and W.W. Chin Regulated specific protein binding to a conserved region of the 3′-untranslated region of thyrotropin beta-subunit mRNA Mol. Endocrinol. 9 1995 375 387
19. S.T. Crooke, M.J. Graham, J.E. Zuckerman, D. Brooks, B.S. Conklin, and L.L. Cummins Pharmacokinetic properties of several novel oligonucleotide analogs in mice J. Pharmacol. Exp. Ther. 277 1996 923 937
20. S. Agrawal, and R.P. Iyer Perspectives in antisense therapeutics Pharmacol. Ther. 76 1997 151 160
21. S. Agrawal, Z. Jiang, Q. Zhao, D. Shaw, Q. Cai, and A. Roskey Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies Proc. Natl. Acad. Sci. U. S. A. 94 1997 2620 2625
22. S.P. Henry, M.V. Templin, N. Gillett, J. Rojko, and A.A. Levin Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1 Toxicol. Pathol. 27 1999 95 100
23. D.J. Hnatowich Antisense and nuclear medicine J. Nucl. Med. 40 1999 693 703
24. A.J. Mouland, S. Beven, J.H. White, and G.N. Hendy Human chromogranin A gene J. Biol. Chem. 269 1994 6918 6926
25. 125I-labeled oligonucleotides from tributylstannylbenzamide conjugates Bioconjug. Chem. 8 1997 238 243
26. S.T. Crooke Therapeutic applications of oligonucleotides Annu. Rev. Pharmacol. Toxicol. 32 1992 329 376